Creat takeover of Biotest closed

  • Transfer of tendered shares completed
  • Majority shareholding (approx. 90% of Biotest AG’s ordinary shares and voting share capital) of Creat in Biotest

Dreieich, 31 January 2018. On 19 January 2018 Biotest AG disclosed that the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisition company of the Creat Group Corporation. Thus the unsolicited takeover offer announced on 18 May 2017 for the shares of Biotest AG became effective and could be settled.
The offer by Tiancheng (Germany) Pharmaceutical Holdings AG and payment of the purchase price to the custodial bank of the accepting Biotest shareholders was settled promptly and, as described in section 13.5 of the offer document.
Tiancheng (Germany) Pharmaceutical Holdings AG, an indirect controlled subsidiary of Creat Group Corporation, a company organized and existing under the laws of the People’s Republic of China, hereby holds a majority interest (approx. 90% of Biotest AG’s ordinary shares and voting share capital) in Biotest AG.

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT-595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT-595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Fibrinogen (BT-524) - Acquired Fibrinogen Deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis
Trimodulin (BT-086) - Severe community acquired pneumonia
(BT-063) - Systemic lupus erythematosus
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
Tregalizumab (BT-061) - other diseases

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Phase IIa study demonstrates favorable safety and toler...

19.07.2018,

Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)- Study meets primary endpoint for sa ... [More]

Biotest AG opens third plasma collection centre in Czec...

20.06.2018,

Biotest AG opens third plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 20 June 2018. Biotest received an operating permit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

20.06.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Large data analysis for DSA after lung transplantation ...

29.05.2018,

Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)- The development of donor specific antibodies (DSA) can lead to graft rejection and thus ... [More]

Efficacy and safety of Cytotect(R) CP was demonstrated ...

23.05.2018,

Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation- 78% of "difficult-to-treat" patients responded to Cytotect(R) CP administration- 70% of patients cle ... [More]

Biotest increases revenues in the first quarter 2018 by...

15.05.2018,

Biotest increases revenues in the first quarter 2018 by 34%- Guidance confirmed- Q1 EBIT totalled to EUR -3.0 million after EUR-33.2 million in Q1 2017Dreieich, 15 May 2018. In the first quarter of 20 ... [More]

Biotest AG: Annual general meeting approves payout of d...

15.05.2018,

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 15 May 2018. At the annual general meeting (AGM) held on 15 M ... [More]

New data from Biotest's monoclonal antibody-drug-conjug...

03.05.2018,

New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors- Good tolerability and signs of efficacy in phase I/IIa clinical study- Very good effectiveness w ... [More]

Biotest reaches 2017 profit guidance

22.03.2018,

Biotest reaches 2017 profit guidance- Adjusted EBIT stable- Five new plasmapheresis centres opened in Europe- Biotest Next Level: building acceptance obtained and successful "Good Manufacturing Practi ... [More]

First patient with acquired fibrinogen deficiency treat...

15.03.2018,

First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG - Important milestone reached in the clinical development programme of fibrinogen concentrate- Phase ... [More]

Biotest supports a large international registry study t...

13.03.2018,

 Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections- High medical need due to high mortality and large pati ... [More]

Biotest reaches FY 2017 EBIT guidance

27.02.2018,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest reaches FY 2017 EBIT guidanceDreieich, 27 February 2018. According to preliminary and unaudited figures, the Biotest ... [More]

Tiancheng intends to enter into a domination and profit...

08.02.2018,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AGDreieich, 8 February 2018. ... [More]

Release according to Article 40, Section 1 of the WpHG ...

02.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

01.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Creat takeover of Biotest closed

31.01.2018,

 Creat takeover of Biotest closed- Transfer of tendered shares completed- Majority shareholding (approx. 90% of Biotest AG's ordinary shares and voting share capital) of Creat in Biotest Dre ... [More]

Biotest AG opens second plasma collection centre in Cze...

24.01.2018,

Biotest AG opens second plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 24 January 2018. Biotest received an operating per ... [More]

All conditions met for Creat takeover of Biotest

19.01.2018,

Announcement according to Article 17 European Market Abuse Regulation (MAR)All conditions met for Creat takeover of BiotestDreieich, 19. January 2018. Biotest AG disclosed today that foreign trade app ... [More]

Release according to Article 40, Section 1 of the WpHG ...

11.01.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Trimodulin: concept for phase III study successfully co...

20.12.2017,

Trimodulin: concept for phase III study successfully coordinated with the authorities- Clinical concept of the Phase III study is supported by the regulatory authorities- Optimized production process ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.